‘Good news’ for pharma companies as UPC provides clarity on imminent infringement
An appeal ruling overturning a decision to allow rival medical treatments to be sold early will be welcomed by pharmaceutical firms for providing clarity as to activities that may constitute imminent infringement of a patent, experts have said.
